Jump to content

Why Pfizer’s ultra-cold COVID-19 vaccine will not be at the local pharmacy any time soon


Recommended Posts

Why Pfizer’s ultra-cold COVID-19 vaccine will not be at the local pharmacy any time soon

By Carl O'Donnell

 

2020-11-10T085508Z_3_LYNXMPEGA81T7_RTROPTP_4_HEALTH-CORONAVIRUS-VACCINES-PFIZER.JPG

A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri

 

NEW YORK (Reuters) - Work to distribute the experimental COVID-19 vaccine developed by Pfizer Inc and BioNTech SE is gearing up after the companies announced successful interim data earlier on Monday, but it will not be coming to local pharmacies for the general public any time soon.

 

The data, which sent U.S. stocks to record highs [.N], showed that the two companies' experimental vaccine is 90% effective at preventing COVID-19. They are still awaiting data on safety, which could come later this month.

 

Pfizer and BioNTech need to get regulators to sign off on the shot before it can start shipping vaccines to those considered most in need by government. Healthcare workers and people living in nursing homes will likely top that list.

 

But the vaccine's complex and super-cold storage requirements are an obstacle for even the most sophisticated hospitals in the United States and may impact when and where it is available in rural areas or poor countries where resources are tight.

 

The main issue is that the vaccine, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, needs to be kept at minus 70 degrees Celsius (-94 F) or below.

 

"The cold chain is going to be one of the most challenging aspects of delivery of this vaccination," said Amesh Adalja, senior scholar at Johns Hopkins Center for Health Security.

 

"This will be a challenge in all settings because hospitals even in big cities do not have storage facilities for a vaccine at that ultra-low temperature."

 

Indeed, one of the most prestigious U.S. hospitals, the Mayo Clinic in Rochester, Minnesota, said it does not currently have that capability.

 

"We're talking about a vaccine that needs storage at minus 70 or 80. That's a tremendous logistical issue not only in the U.S. but outside the Western world," said Dr Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic.

 

"We're a major medical center and we don't have storage capacity like this. That will be true for everybody. This is a logistical obstacle."

 

Pfizer spokeswoman Kim Bencker said the company was working closely with the U.S. government and state officials on how to ship the vaccine from its distribution centers in the United States, Germany and Belgium around the globe.

 

The detailed plan includes using dry ice to transport frozen vaccine vials by both air and land at their recommended temperatures for up to 10 days, she said.

 

ON ICE

 

State and local healthcare providers are responsible for storing and administering vaccines once delivered.

 

They can be kept in an ultra-low temperature freezer for up to six months, or for five days at 2-8 degrees C – a type of refrigeration commonly available at hospitals, Bencker said.

 

The Pfizer storage units can also be refilled with ice for up to 15 days, she said.

 

But shots will spoil in around five days at normal refrigeration temperatures of slightly above freezing. BioNTech CEO Ugur Sahin told Reuters the companies are analyzing if they can extend that for two weeks.

 

The vaccine of Moderna Inc, which is working on a vaccine based on similar technology, does not need to be stored at such a low temperature.

 

Other vaccines including ones from Johnson & Johnson and Novavax Inc can be stored at 2-8 degrees C, the temperature of a regular refrigerator.

 

EXPANSION

 

Northwell Health, a major hospital system in New York, is expanding its ultra-cold storage capacity. Although it is possible to deploy the vaccine before it spoils, Northwell Chief Pharmacy Officer Onisis Stefas said the hospital decided the freezer access would ensure a smooth rollout.

 

The cold storage requirements could impede Pfizer’s ability to reach rural healthcare systems and nursing homes, or less wealthy nations, which may not have the funds for the refrigeration units, experts said.

 

"If Pfizer’s is the only vaccine to be authorized in the next few months, we do worry about equity when it comes to spreading it to rural areas,” said Claire Hannan, executive director at the Association of Immunization Managers, a lobbying group for local public health officials who handle vaccines.

 

Ultra-cold freezer supplies are already limited as hospitals scramble to stock up, Stefas said.

 

Some states have said they have a shortage of ultra-cold freezers, according to public documents that states filed with the U.S. Centers for Disease Control.

 

New Hampshire has purchased extra ultra-cold freezers and like other states is lobbying the Trump administration for additional funds, the documents show.

 

California has also said ultra-cold freezer supplies are limited and roughly half of the states’ health departments are looking in to purchasing or leasing additional cold storage supplies.

 

It has proposed building a distribution network of ultra-cold freezers, including mobile vaccination clinics, to reach underserved areas around the state. California said it will not provide vaccine supplies to facilities without adequate cold-storage capabilities.

 

Without the extra equipment, doctors will have a dilemma: store vaccines in standard refrigerators and deploy all 975 doses in each Pfizer vaccine container in less than five days or restock them with dry ice and open them only twice a day to extend the vaccines’ life span, Hannan said.

 

"I think it will be difficult, but based on the task and how important it is, people will do the best to their ability to make that happen," Stefas said.

 

reuters_logo.jpg

-- © Copyright Reuters 2020-11-10
 
Link to post
Share on other sites
  • Replies 32
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Popular Posts

Nonsense. 90 percent is a pipe dream that they had no idea they could attain. Its a dream result - 60 to 70 percent would be excellent. Please, stop spreading your prison planet nonsens

Not good enough they need to be 100% effective to be any good for everybody .

90% is considered quite good.  A lot of people were hoping for something that is at least 60% effective. I don't think 100% is realistic for any vaccine.

Posted Images

The -80 degree C is the major issue here.

 

There is one that requires nothing like this, it's the one known as ChAdOx1 during development, I can't recall offhand what temperature it requires but it's nothing like the extreme -80 C.....

 

Link to post
Share on other sites
9 minutes ago, impulse said:

 

By the time we read about stuff like this, the news is already built into that stock price.  Probably already oversubscribed, with early entrants ready to dump their stock and take their profits.

 

on that kind of indirect information, the effect is much slower, especially if you choose manufacturers with a local market.

 

the market doesn't react as fast as a commodities market reacts to war in the middle east or a draught.

Edited by tgw
Link to post
Share on other sites
12 hours ago, rabas said:

 

 

You would think if man can create custom mRNA codes to program your cells and pack it into nano lipid balls, they could figure out how to work at dry ice temperatures.  It may be more a bureaucracy and logistics problem:

 

 

It is an engineering problem mixed in with a pharma problem. Either they find a neat engineering solution to keeping the shots at the ultra low temperature or they find a way of tweaking the vaccine so that it does not have to be kept at such ultra low temperatures. Neither have to do really with bureaucracy or logistics.

Link to post
Share on other sites
19 hours ago, keith101 said:

Not good enough they need to be 100% effective to be any good for everybody .

Compared to a quote of around 60-70% concerning masles...... 90% with the German vaccine is brilliant. 

Flu injection will give you only around 30-50% effectiveness. 

 

 

 

Link to post
Share on other sites
2 hours ago, sawadee1947 said:

Compared to a quote of around 60-70% concerning masles...... 90% with the German vaccine is brilliant. 

Flu injection will give you only around 30-50% effectiveness. 

 

 

 

Indeed, no vaccine is 100% effective. But people overlook another major factor: an efficacy of 90% (the accuracy of which is questionable as we talk about very small numbers) would be great IF everyone was vaccinated (in the shorter time this is not feasible anyway so will likely be restricted to certain risk groups).  If, however, 50% refuses to do so, it will only reduce the number of deaths. 

    The cold storage requirements for the Pfizer stuff present a further hurdle, in Germany for instance there is now talk of setting up a few specialized centres with the proper facilities. You will be unlikely to get a jab at your local doctor. In developing countries with limited facilities the transport/storage will likely be a major hurdle. 

  • Like 2
Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    No registered users viewing this page.


×
×
  • Create New...